RET codon 609 mutations: a contribution for better clinical managing

Detalhes bibliográficos
Autor(a) principal: Mian, Caterina
Data de Publicação: 2012
Outros Autores: Sartorato, Paola, Barollo, Susi, Zane, Mariangela, Opocher, Giuseppe
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/19718
Resumo: Medullary thyroid carcinoma currently accounts for 5-8% of all thyroid cancers. The clinical course of this disease varies from extremely indolent tumors that can go unchanged for years to an extremely aggressive variant that is associated with a high mortality rate. As many as 75% of all medullary thyroid carcinomas are sporadic, with an average age at presentation reported as 60 years, and the remaining 25% are hereditary with an earlier age of presentation, ranging from 20 to 40 years. Germline RET proto-oncogene mutations are the genetic causes of multiple endocrine neoplasia type 2 and a strong genotype-phenotype correlation exists, particularly between a specific RET codon mutation and the (a) age-related onset and (b) thyroid tumor progression, from C-cell hyperplasia to medullary thyroid carcinoma and, ultimately, to nodal metastases. RET mutations predispose an individual to the development of medullary thyroid carcinomas and can also influence the individual response to RET protein receptor-targeted therapies. RET codon 609point mutations are rare genetic events belonging to the intermediate risk category for the onset of medullary thyroid carcinoma. A large genealogy resulting in a less aggressive form of medullary thyroid carcinoma is associated with the high penetrance of pheochromocytoma and has been reported in the literature. In this short review article, we comment on our previous report of a large multiple endocrine neoplasia type 2A kindred with the same Cys609Ser germline RET mutation in which, conversely, the syndrome was characterized by a slightly aggressive, highly penetrant form of medullary thyroid carcinoma that was associated with low penetrance of pheochromocytoma and primary hyperparathyroidism.
id USP-19_c2b515d674e8907e8e839e7e39c337f7
oai_identifier_str oai:revistas.usp.br:article/19718
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling RET codon 609 mutations: a contribution for better clinical managingPheochromocytomaMEN2AMedullary Thyroid CarcinomaHereditary Thyroid CancerMedullary thyroid carcinoma currently accounts for 5-8% of all thyroid cancers. The clinical course of this disease varies from extremely indolent tumors that can go unchanged for years to an extremely aggressive variant that is associated with a high mortality rate. As many as 75% of all medullary thyroid carcinomas are sporadic, with an average age at presentation reported as 60 years, and the remaining 25% are hereditary with an earlier age of presentation, ranging from 20 to 40 years. Germline RET proto-oncogene mutations are the genetic causes of multiple endocrine neoplasia type 2 and a strong genotype-phenotype correlation exists, particularly between a specific RET codon mutation and the (a) age-related onset and (b) thyroid tumor progression, from C-cell hyperplasia to medullary thyroid carcinoma and, ultimately, to nodal metastases. RET mutations predispose an individual to the development of medullary thyroid carcinomas and can also influence the individual response to RET protein receptor-targeted therapies. RET codon 609point mutations are rare genetic events belonging to the intermediate risk category for the onset of medullary thyroid carcinoma. A large genealogy resulting in a less aggressive form of medullary thyroid carcinoma is associated with the high penetrance of pheochromocytoma and has been reported in the literature. In this short review article, we comment on our previous report of a large multiple endocrine neoplasia type 2A kindred with the same Cys609Ser germline RET mutation in which, conversely, the syndrome was characterized by a slightly aggressive, highly penetrant form of medullary thyroid carcinoma that was associated with low penetrance of pheochromocytoma and primary hyperparathyroidism.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2012-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/1971810.6061/clinics/2012(Sup01)07Clinics; Vol. 67 No. supl.1 (2012); 33-36Clinics; v. 67 n. supl.1 (2012); 33-36Clinics; Vol. 67 Núm. supl.1 (2012); 33-361980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/19718/21782Mian, CaterinaSartorato, PaolaBarollo, SusiZane, MariangelaOpocher, Giuseppeinfo:eu-repo/semantics/openAccess2012-05-24T20:33:31Zoai:revistas.usp.br:article/19718Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2012-05-24T20:33:31Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv RET codon 609 mutations: a contribution for better clinical managing
title RET codon 609 mutations: a contribution for better clinical managing
spellingShingle RET codon 609 mutations: a contribution for better clinical managing
Mian, Caterina
Pheochromocytoma
MEN2A
Medullary Thyroid Carcinoma
Hereditary Thyroid Cancer
title_short RET codon 609 mutations: a contribution for better clinical managing
title_full RET codon 609 mutations: a contribution for better clinical managing
title_fullStr RET codon 609 mutations: a contribution for better clinical managing
title_full_unstemmed RET codon 609 mutations: a contribution for better clinical managing
title_sort RET codon 609 mutations: a contribution for better clinical managing
author Mian, Caterina
author_facet Mian, Caterina
Sartorato, Paola
Barollo, Susi
Zane, Mariangela
Opocher, Giuseppe
author_role author
author2 Sartorato, Paola
Barollo, Susi
Zane, Mariangela
Opocher, Giuseppe
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Mian, Caterina
Sartorato, Paola
Barollo, Susi
Zane, Mariangela
Opocher, Giuseppe
dc.subject.por.fl_str_mv Pheochromocytoma
MEN2A
Medullary Thyroid Carcinoma
Hereditary Thyroid Cancer
topic Pheochromocytoma
MEN2A
Medullary Thyroid Carcinoma
Hereditary Thyroid Cancer
description Medullary thyroid carcinoma currently accounts for 5-8% of all thyroid cancers. The clinical course of this disease varies from extremely indolent tumors that can go unchanged for years to an extremely aggressive variant that is associated with a high mortality rate. As many as 75% of all medullary thyroid carcinomas are sporadic, with an average age at presentation reported as 60 years, and the remaining 25% are hereditary with an earlier age of presentation, ranging from 20 to 40 years. Germline RET proto-oncogene mutations are the genetic causes of multiple endocrine neoplasia type 2 and a strong genotype-phenotype correlation exists, particularly between a specific RET codon mutation and the (a) age-related onset and (b) thyroid tumor progression, from C-cell hyperplasia to medullary thyroid carcinoma and, ultimately, to nodal metastases. RET mutations predispose an individual to the development of medullary thyroid carcinomas and can also influence the individual response to RET protein receptor-targeted therapies. RET codon 609point mutations are rare genetic events belonging to the intermediate risk category for the onset of medullary thyroid carcinoma. A large genealogy resulting in a less aggressive form of medullary thyroid carcinoma is associated with the high penetrance of pheochromocytoma and has been reported in the literature. In this short review article, we comment on our previous report of a large multiple endocrine neoplasia type 2A kindred with the same Cys609Ser germline RET mutation in which, conversely, the syndrome was characterized by a slightly aggressive, highly penetrant form of medullary thyroid carcinoma that was associated with low penetrance of pheochromocytoma and primary hyperparathyroidism.
publishDate 2012
dc.date.none.fl_str_mv 2012-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/19718
10.6061/clinics/2012(Sup01)07
url https://www.revistas.usp.br/clinics/article/view/19718
identifier_str_mv 10.6061/clinics/2012(Sup01)07
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/19718/21782
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 67 No. supl.1 (2012); 33-36
Clinics; v. 67 n. supl.1 (2012); 33-36
Clinics; Vol. 67 Núm. supl.1 (2012); 33-36
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222758286655489